AYTU BIOPHARMA, INC Inventory Write-down
AYTU BIOPHARMA, INC (AYTU) reported Inventory Write-down of $2.19 million for the 12-month period ending 2026-06-30, per its 10-K filed 2026-09-22.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:InventoryWriteDown · last filed 2026-09-22
- AYTU BIOPHARMA, INC inventory write-down for the quarter ending 2026-06-30 was $421.00K, a 196.48% increase year-over-year.
- AYTU BIOPHARMA, INC inventory write-down for the quarter ending 2026-03-31 was $700.00K, a 600.00% increase year-over-year.
- AYTU BIOPHARMA, INC inventory write-down for the quarter ending 2025-12-31 was $800.00K, a 700.00% increase year-over-year.
- AYTU BIOPHARMA, INC inventory write-down for the quarter ending 2025-09-30 was $278.00K, a 308.82% increase year-over-year.
- AYTU BIOPHARMA, INC inventory write-down for fiscal 2026 was $2.19M, a 572.92% increase from fiscal 2025.
- AYTU BIOPHARMA, INC inventory write-down for fiscal 2025 was $325.00K, a 72.67% decline from fiscal 2024.
- AYTU BIOPHARMA, INC inventory write-down for fiscal 2024 was $1.19M, a 49.43% decline from fiscal 2023.
- AYTU BIOPHARMA, INC inventory write-down for fiscal 2023 was $2.35M, a 7.55% increase from fiscal 2022.
| Period end | Inventory Write-down 3 month | Inventory Write-down 3 month as first filed | Inventory Write-down 6 month | Inventory Write-down 6 month as first filed | Inventory Write-down 9 month | Inventory Write-down 9 month as first filed | Inventory Write-down 12 month | Inventory Write-down 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $421.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $1.12M derived: sum of 2 quarters · filed 2026-09-22 | $1.92M derived: sum of 3 quarters · filed 2026-09-22 | $2.19M 10-K · filed 2026-09-22 | ||||
| 2026-03-31 | $700.00K 10-Q · filed 2026-05-13 | $1.50M derived: sum of 2 quarters · filed 2026-05-13 | $1.77M 10-Q · filed 2026-05-13 | $1.92M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-12-31 | $800.00K 10-Q · filed 2026-02-03 | $1.11M 10-Q · filed 2026-02-03 | $1.22M derived: sum of 3 quarters · filed 2026-09-22 | $1.32M derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-09-30 | $278.00K 10-Q · filed 2025-11-13 | $420.00K derived: sum of 2 quarters · filed 2026-09-22 | $520.00K derived: sum of 3 quarters · filed 2026-09-22 | $620.00K derived: sum of 4 quarters · filed 2026-09-22 | ||||
| 2025-06-30 | $142.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-09-22 | $242.00K derived: sum of 2 quarters · filed 2026-09-22 | $342.00K derived: sum of 3 quarters · filed 2026-09-22 | $325.00K 10-K · filed 2026-09-22 | ||||
| 2025-03-31 | $100.00K 10-Q · filed 2026-05-13 | $200.00K derived: sum of 2 quarters · filed 2026-05-13 | $183.00K 10-Q · filed 2026-05-13 | $1.33M derived: sum of 4 quarters · filed 2026-05-13 | ||||
| 2024-12-31 | $100.00K 10-Q · filed 2026-02-03 | $95.00K 10-Q · filed 2026-02-03 | $1.23M derived: sum of 3 quarters · filed 2026-02-03 | $1.33M derived: sum of 4 quarters · filed 2026-02-03 | ||||
| 2024-09-30 | $68.00K 10-Q · filed 2025-11-13 | $100.00K 10-Q · filed 2024-11-13 | $1.13M derived: sum of 2 quarters · filed 2025-11-13 | $68.00K 10-Q · filed 2024-11-13 | $1.33M derived: sum of 4 quarters · filed 2025-11-13 | |||
| 2024-06-30 | $1.06M derived: 10-K 12 month − 10-Q 9 month · filed 2025-09-23 | $1.16M derived: sum of 2 quarters · filed 2025-09-23 | $1.26M derived: sum of 3 quarters · filed 2025-09-23 | $1.19M 10-K · filed 2025-09-23 | $2.27M 10-K · filed 2024-09-26 | |||
| 2024-03-31 | $100.00K 10-Q · filed 2025-05-14 | $300.00K 10-Q · filed 2024-05-15 | $200.00K derived: sum of 2 quarters · filed 2025-05-14 | $125.00K 10-Q · filed 2025-05-14 | $476.00K 10-Q · filed 2024-05-15 | $2.45M derived: sum of 4 quarters · filed 2025-05-14 | ||
| 2023-12-31 | $100.00K 10-Q · filed 2025-02-12 | $51.00K 10-Q · filed 2025-02-12 | $133.00K 10-Q · filed 2024-02-14 | $2.35M derived: sum of 3 quarters · filed 2025-02-12 | $2.45M derived: sum of 4 quarters · filed 2025-02-12 | |||
| 2023-09-30 | $100.00K 10-Q · filed 2024-11-13 | $51.00K 10-Q · filed 2023-11-14 | $2.25M derived: sum of 2 quarters · filed 2024-11-13 | $51.00K 10-Q · filed 2024-11-13 | $2.35M derived: sum of 4 quarters · filed 2024-11-13 | |||
| 2023-06-30 | $2.15M derived: 10-K 12 month − 10-Q 9 month · filed 2024-09-26 | $2.25M derived: sum of 2 quarters · filed 2024-09-26 | $2.25M derived: sum of 3 quarters · filed 2024-09-26 | $2.35M 10-K · filed 2024-09-26 | ||||
| 2023-03-31 | $100.00K 10-Q · filed 2024-05-15 | $100.00K derived: sum of 2 quarters · filed 2024-05-15 | $199.00K 10-Q · filed 2024-05-15 | $2.02M derived: sum of 4 quarters · filed 2024-05-15 | ||||
| 2022-12-31 | $0.00 10-Q · filed 2024-02-14 | $82.00K 10-Q · filed 2024-02-14 | $1.92M derived: sum of 3 quarters · filed 2024-02-14 | $1.92M derived: sum of 4 quarters · filed 2024-02-14 | ||||
| 2022-09-30 | $82.00K 10-Q · filed 2023-11-14 | $1.92M derived: sum of 2 quarters · filed 2023-11-14 | $1.92M derived: sum of 3 quarters · filed 2023-11-14 | $2.02M derived: sum of 4 quarters · filed 2023-11-14 | ||||
| 2022-06-30 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2023-10-12 | $1.84M derived: sum of 2 quarters · filed 2023-10-12 | $1.94M derived: sum of 3 quarters · filed 2023-10-12 | $2.19M 10-K · filed 2023-10-12 | ||||
| 2022-03-31 | $3.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-05-11 | $103.00K derived: sum of 2 quarters · filed 2023-05-11 | $352.00K 10-Q · filed 2023-05-11 | $411.00K derived: sum of 4 quarters · filed 2023-05-11 | ||||
| 2021-12-31 | $100.00K 10-Q · filed 2022-02-14 | $349.00K 10-Q · filed 2023-02-21 | $408.00K derived: sum of 3 quarters · filed 2023-02-21 | $7.41M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-09-30 | $203.00K 10-Q/A · filed 2023-02-21 | $308.00K derived: sum of 2 quarters · filed 2023-02-21 | $7.31M derived: sum of 3 quarters · filed 2023-02-21 | $7.31M derived: sum of 4 quarters · filed 2023-02-21 | ||||
| 2021-06-30 | $105.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-09-27 | $7.11M derived: sum of 2 quarters · filed 2022-09-27 | $7.11M derived: sum of 3 quarters · filed 2022-09-27 | $7.33M 10-K · filed 2022-09-27 | ||||
| 2021-03-31 | $7.00M 10-Q · filed 2022-05-16 | $7.00M derived: sum of 2 quarters · filed 2022-05-16 | $7.23M 10-Q · filed 2022-05-16 | $7.23M 10-Q · filed 2021-05-17 | ||||
| 2020-12-31 | $0.00 10-Q · filed 2022-02-14 | $99.00K 10-Q · filed 2022-02-14 | $200.00K 10-Q · filed 2021-02-11 | |||||
| 2020-12-30 | $100.00K 10-Q · filed 2021-02-11 | $199.00K derived: sum of 2 quarters · filed 2021-11-15 | $1.46M derived: sum of 3 quarters · filed 2021-11-15 | $1.46M derived: sum of 4 quarters · filed 2021-11-15 | ||||
| 2020-09-30 | $99.00K 10-Q · filed 2021-11-15 | $100.00K 10-Q · filed 2020-11-12 | $1.36M derived: sum of 2 quarters · filed 2021-11-15 | $1.36M derived: sum of 3 quarters · filed 2021-11-15 | $1.36M derived: sum of 4 quarters · filed 2021-11-15 | |||
| 2020-06-30 | $1.26M derived: 10-K 12 month − 10-Q 9 month · filed 2021-09-28 | $1.26M derived: sum of 2 quarters · filed 2021-09-28 | $1.26M derived: sum of 3 quarters · filed 2021-09-28 | $1.26M 10-K · filed 2021-09-28 | ||||
| 2020-03-31 | $0.00 10-Q · filed 2021-05-17 | $0.00 derived: sum of 2 quarters · filed 2021-05-17 | $0.00 10-Q · filed 2021-05-17 | |||||
| 2019-12-31 | $0.00 10-Q · filed 2021-02-11 | $0.00 10-Q · filed 2021-02-11 | ||||||
| 2019-09-30 | $0.00 10-Q · filed 2020-11-12 | |||||||
| 2019-03-31 | $0.00 10-Q · filed 2020-05-15 | $0.00 derived: sum of 2 quarters · filed 2020-05-15 | $0.00 10-Q · filed 2020-05-15 | |||||
| 2018-12-31 | $0.00 10-Q · filed 2020-02-14 | $0.00 10-Q · filed 2020-02-14 | ||||||
| 2018-09-30 | $0.00 10-Q · filed 2019-11-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NextCure, Inc. (NXTC) | United States | $0.024B | -0.15 |
| TherapeuticsMD, Inc. (TXMD) | United States | $0.024B | -117.87 |
| ARTELO BIOSCIENCES, INC. (ARTL) | United States | $0.023B | |
| KYNTRA BIO, INC. (KYNB) | United States | $0.028B | 0.17 |
| Transcode Therapeutics, Inc. (RNAZ) | United States | $0.029B | -0.12 |
| Cocrystal Pharma, Inc. (COCP) | United States | $0.022B | |
| Hepion Pharmaceuticals, Inc. (HEPA) | United States | $0.029B | -0.62 |
| ATOSSA THERAPEUTICS, INC. (ATOS) | United States | $0.021B | -0.52 |
| IGC Pharma, Inc. (IGC) | United States | $0.029B | -5.98 |
| Neuphoria Therapeutics Inc. (NEUP) | United States | $0.020B | -1.77 |